Home > Boards > US OTC > Biotechs > Cytodyn Inc. (CYDY)

Harish Seethamraju, M.D., Medical Director for the Mount

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
JPG77 Member Profile
 
Followed By 18
Posts 1,769
Boards Moderated 1
Alias Born 05/08/15
160x600 placeholder
CytoDyn to conduct two COVID-19 trials in Brazil Seeking Alpha - 5/5/2021 6:25:40 AM
CytoDyn provides updates on leronlimab HIV extension arm; to hold webcast on May 5 on multiple initiatives Seeking Alpha - 5/3/2021 9:46:59 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/29/2021 4:32:06 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/21/2021 6:28:13 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/21/2021 4:31:54 PM
CytoDyn initiates rolling submission of leronlimab in COVID-19 to Canada regulator Seeking Alpha - 4/19/2021 6:54:58 AM
CytoDyn executes supply and distribution agreement with Chiral Pharma Seeking Alpha - 4/15/2021 9:34:25 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/12/2021 4:31:04 PM
CytoDyn completes enrollment in COVID-19 long-hauler trial Seeking Alpha - 4/9/2021 6:59:31 AM
CytoDyn updates on leronlimab-treated COVID-19 patient Seeking Alpha - 4/5/2021 11:51:19 AM
CytoDyn to provide full update on its activities on April 6 Seeking Alpha - 4/1/2021 6:19:48 AM
CytoDyn files new protocol with FDA for 4 doses of leronlimab for critical COVID-19 Seeking Alpha - 4/1/2021 6:13:14 AM
CytoDyn’s leronlimab reduces mortality by 82% at 14 days in critically ill COVID-19 patients Seeking Alpha - 3/30/2021 7:08:56 AM
Philippines OKs use of CytoDyn's leronlimab in COVID-19 Seeking Alpha - 3/29/2021 6:30:52 AM
Nextech AR (OTCQB: NEXCF) Doubling Sales - Emerging Growth Report InvestorsHub NewsWire - 3/24/2021 6:45:37 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 3/18/2021 7:46:16 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/16/2021 8:31:13 AM
CytoDyn promotes from within for COO role Seeking Alpha - 3/16/2021 6:03:45 AM
Nextech AR (OTCQB: NEXCF) $13 million Deal, The Next Short Squeeze InvestorsHub NewsWire - 3/11/2021 7:53:20 AM
Enrollment underway in CytoDyn’s long-haulers COVID-19 trial Seeking Alpha - 3/11/2021 5:49:54 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/8/2021 5:28:38 PM
CytoDyn to release CD12 trial data on March 8 Seeking Alpha - 3/8/2021 6:34:51 AM
CytoDyn to file for rolling review of leronlimab in COVID-19 in U.S., U.K. and Canada Seeking Alpha - 3/7/2021 11:56:10 PM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 3/3/2021 5:23:39 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/2/2021 8:32:38 AM
JPG77   Saturday, 03/06/21 09:09:44 AM
Re: None
Post # of 164279 
Harish Seethamraju, M.D., Medical Director for the Mount Sinai Lung Transplantation Program, commented, “The CD12 trial results are very promising and leronlimab may be the only safe medication to help critically ill patients.”

In my opinion (and Dr Seethamraju's), this says it all. Clearly the medical community interprets the CD12 results as "very promising", and I doubt the FDA sees it differently.

My comments are just my opinions and should NOT be taken as investment advice.
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences